Business
NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO Transaction
Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) &#...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar's Debts Prior to RTO TransactionCalgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or \"EnerSpar\") (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed price of CAD$0.80 per share to settle indebtedness of CAD$136,155.83 owed to certain senior officers, directors, creditors, and consultants of EnerSpar.The debts were incurred during EnerSpar operations prior to the recent Reverse Takeover Transaction under which NurExone began trading under the new name \"NurExone Biologic Inc.\" with the trading symbol \"NRX\". An additional CAD$65,000 of EnerSpar's debt is being repaid by the Company in cash according to an agreed payment schedule. The price per share of the debt offering is at approximately a 100% premium over the current share price. Completion of the transaction is subject to customary conditions including approval of the TSX Venture Exchange. The common shares will be issued upon acceptance by the TSX Venture Exchange. The common shares issued will be subject to a four-month plus one-day hold period pursuant to the policies of the TSX Venture Exchange.The shares for the debt transaction involving Jay Richardson will be a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions (\"MI 61-101\") as Jay Richardson is a current director of NurExone who will subscribe for an aggregate of an estimated 117,033 common shares in settlement of indebtedness of CAD$93,626. However, the issuance is exempt from: (i) the valuation requirement of MI 61-101 by virtue of the exemption contained in Section 5.5(b), as the Shares are not listed on a market specified in MI 61-101, and (ii) from the minority shareholder approval requirement of MI 61-101 by virtue of the exemption contained in Section 5.7(1)(a) of MI 61-101, as the fair market value of the Shares does not exceed 25% of the Company's market capitalization. The participation by the Related Parties in the shares for debt transactions has been approved by directors ...